Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

por Jacob K. Jensen, Emilie H. Zobel, Emilie H. Zobel, Bernt J. von Scholten, Bernt J. von Scholten, Viktor Rotbain Curovic, Tine W. Hansen, Peter Rossing, Andreas Kjaer, Rasmus S. Ripa
Publicado 2021

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

por Emilie H. Zobel, Rasmus S. Ripa, Bernt J. von Scholten, Viktor Rotbain Curovic, Andreas Kjaer, Tine W. Hansen, Peter Rossing, Joachim Størling
Publicado 2021

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

por Andreas Kjær, Peter Rossing, Emilie H Zobel, Asger Wretlind, Rasmus S Ripa, Viktor Rotbain Curovic, Bernt J von Scholten, Tommi Suvitaival, Tine W Hansen, Cristina Legido-Quigley
Publicado 2021